Concepedia

Publication | Closed Access

Irofulven Demonstrates Clinical Activity Against Metastatic Hormone-Refractory Prostate Cancer in a Phase 2 Single-Agent Trial

DOI

39

Citations

19

References

2005

Year

Neil Senzer, James C. Arsenau, Donald Richards, Barry S. Berman, John R. MacDonald, Sheri L. Smith
American Journal of Clinical Oncology

Abstract

Irofulven shows activity in hormone-refractory prostate cancer and has an acceptable safety profile, warranting further investigation of this drug, particularly in combination therapies.

References

YearCitations

Page 1